Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn’s Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.

Safety and efficacy of sucrosomal iron in inflammatory bowel disease patients with iron deficiency anemia / Abbati, G.; Incerti, F.; Boarini, C.; Bocchi, D.; Ventura, P.; Buzzetti, E.; Pietrangelo, A.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - 14:3(2019), pp. 423-431.

Safety and efficacy of sucrosomal iron in inflammatory bowel disease patients with iron deficiency anemia

Abbati G.
Writing – Original Draft Preparation
;
Boarini C.;Bocchi D.;Ventura P.
Formal Analysis
;
Buzzetti E.;Pietrangelo A.
Supervision
2019

Abstract

Iron deficiency anemia (IDA) is one of the most common complications of inflammatory bowel disease (IBD). We planned a prospective study to address tolerability and efficacy of sucrosomial iron, a new oral formulation of ferric pyrophosphate, in IBD patients. Thirty patients with a confirmed diagnosis of Crohn’s Disease (CD) or ulcerative colitis (UC) and mild IDA were enrolled. Patients with severe IBD were excluded. All patients underwent 12 weeks of oral treatment with 30 mg/day of sucrosomial iron. Treatment compliance and adverse events were investigated every 4 weeks. Iron status, hematological parameters and IBD activity scores were determined at baseline and at the end of treatment, as well as serum hepcidin and non-transferrin bound iron (NTBI) levels. Twenty-four (80%) patients took more than 90% of the prescribed regimen. Forty-four adverse events (AEs) were recorded, but none of them is considered certainly or probably related to the study treatment. Interestingly, only eleven gastrointestinal events were recorded in 9 (30%) patients. At the end of treatment, all iron parameters improved significantly and Hb increased in 86% of patients (from 11.67 to 12.37 g/dl, p = 0.001). Serum hepcidin showed a significant increase in 79% of patients and became positively correlated with C-reactive protein (CRP) at the end of the study, while NTBI remained below the detection threshold after iron supplementation. The IBD activity scores improved in both CD and UC. This pilot interventional study supports the therapeutic use of sucrosomial iron in IBD and paves the way for future studies in larger or more difficult IBD populations.
29-nov-2018
14
3
423
431
Safety and efficacy of sucrosomal iron in inflammatory bowel disease patients with iron deficiency anemia / Abbati, G.; Incerti, F.; Boarini, C.; Bocchi, D.; Ventura, P.; Buzzetti, E.; Pietrangelo, A.. - In: INTERNAL AND EMERGENCY MEDICINE. - ISSN 1970-9366. - 14:3(2019), pp. 423-431.
Abbati, G.; Incerti, F.; Boarini, C.; Bocchi, D.; Ventura, P.; Buzzetti, E.; Pietrangelo, A.
File in questo prodotto:
File Dimensione Formato  
Abbati2019_Article_SafetyAndEfficacyOfSucrosomial.pdf

non disponibili

Tipologia: Versione dell'editore (versione pubblicata)
Dimensione 983.33 kB
Formato Adobe PDF
983.33 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/11380/1167756
Citazioni
  • ???jsp.display-item.citation.pmc??? 8
  • Scopus 14
  • ???jsp.display-item.citation.isi??? 12
social impact